FDA sets date to review first US over-the-counter birth control

U.S. regulators will hold a joint meeting in May to review whether Perrigo Co.’s birth-control product Opill can be sold without a prescription.

The Food and Drug Administration’s Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee will virtually meet on May 9 and May 10 to review the company’s application, according to a company statement on Tuesday.

The FDA did not immediately respond to a request for comment.